To investigate the epigenetic modifications underlying acquired EGFR-TKI resistance in NSCLCs, we administered a series of DNA methylation and histone modification enzyme inhibitors to Erlotinib-resistant NSCLC cells (NSCLC/ER). Here, EGFR is linked to non-small cell lung carcinoma.